Form D · Biotechnology
Nexo Therapeutics, Inc.
Littleton, CO · CIK 0001955319
Offering snapshot reported Mar 27, 2026 · SEC filing
- Reported sold
- $60M Offering amount: $60M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 15, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 27, 2026 | Amendment | $60,000,000 | No comparison | 7 | SEC filing |
| Sep 13, 2024 | Amendment | $45,000,000 | $15,000,000vs Nov 21, 2022 | 6 | SEC filing |
| Nov 21, 2022 | Initial | $30,000,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-465438
Source: Form D, filed Mar 27, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ali Behbahani | Director |
| Michael Kim | Executive |
| Andrew Phillips | Director, Executive |
| Carlo Rizzuto | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11757 W. Ken Caryl Avenue Suite F, 520
Littleton, CO, 80127-3719
Littleton, CO, 80127-3719